Wells Fargo & Company Mesoblast LTD Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$1.0 - $1.39 $63,406 - $88,134	63,406 Added 130.04%	112,163 $123,000
Q3 2023 Nov 13, 2023	SELL	$1.22 - $4.83 $4,948 - $19,590	-4,056 Reduced 7.68%	48,757 $59,000
Q2 2023 Aug 15, 2023	BUY	$2.95 - $4.44 $55,303 - $83,236	18,747 Added 55.03%	52,813 $206,000
Q1 2023 May 12, 2023	BUY	$2.94 - $4.18 $86,630 - $123,167	29,466 Added 640.57%	34,066 $112,000
Q1 2022 May 16, 2022	BUY	$3.58 - $4.98 $6,444 - $8,964	1,800 Added 64.29%	4,600 $19,000
Q4 2021 Feb 14, 2022	BUY	$4.17 - $7.09 $11,196 - $19,036	2,685 Added 2334.78%	2,800 $13,000
Q3 2021 Nov 15, 2021	BUY	$5.87 - $7.85 $675 - $902	115 New	115 $1,000
Q2 2021 Aug 16, 2021	SELL	$6.69 - $9.0 $64,759 - $87,120	-9,680 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$8.26 - $11.4 $19,947 - $27,531	2,415 Added 33.24%	9,680 $80,000
Q4 2020 Feb 09, 2021	SELL	$8.21 - $18.59 $13,858 - $31,379	-1,688 Reduced 18.85%	7,265 $62,000
Q3 2020 Nov 05, 2020	BUY	$11.33 - $19.81 $101,437 - $177,358	8,953 New	8,953 $166,000

151K

Ticker MESO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 147,316,000
Market Cap $2.51B
Description
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its ...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.